non-financial development institution
major organizer of congress and exhibition events
Welcome!
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Халилов Дмитрий
Dmitry Khalilov
Partner, Head of the Group for the Provision of Services to Enterprises of the Consumer Goods Sector, CIS, EY
Quotes
08.06.2019
SPIEF 2019
Priority Strategies in the Supply of Drugs
If research on a drug is followed in a sufficiently thought-through way, then it will be possible to rework the budget in time to use it in the drug supply system. Identifying these drugs at an early stage and then using them in the system can lead to savings of up to 5%
26.05.2018
SPIEF 2018
Life Sciences in 2030: A New Era for Biotechnology
We need certain state-set game rules that will be fixed at least in the medium term. The research takes a rather long period and the state should consistently and purposefully support the companies that will invest in investments
26.05.2018
SPIEF 2018
Life Sciences in 2030: A New Era for Biotechnology
There is no stable regulatory environment in Russia. Still, frequently changing legislation does not keep pace with the development of the market. For example, legislation on biocell technology was adopted only in 2017–18
26.05.2018
SPIEF 2018
Providing Medications to the Russian Population
The objectives set by the President to the Government contain some rather ambitious requests – to increase life expectancy to 78, and to 80 by 2030. We must ensure the provision of medicine to a certain level in order to meet these objectives